<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05067088</url>
  </required_header>
  <id_info>
    <org_study_id>2000024615</org_study_id>
    <secondary_id>1K23HL159259-01</secondary_id>
    <nct_id>NCT05067088</nct_id>
  </id_info>
  <brief_title>Novel physIologiC prEdictors of Positive Airway Pressure Effectiveness</brief_title>
  <acronym>NICEPAP</acronym>
  <official_title>Novel physIologiC prEdictors of Positive Airway Pressure Effectiveness: NICEPAP Study Prospective Cohort</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Millions of Americans suffer from high blood pressure, diabetes, strokes and motor vehicle&#xD;
      accidents due to ineffective treatment of obstructive sleep apnea (OSA). Our preliminary data&#xD;
      suggest that physiological causes of OSA such as easy arousability (low arousal threshold) or&#xD;
      unstable breathing control (high loop gain) may influence effectiveness of OSA's most common&#xD;
      treatment, continuous positive airway pressure (CPAP). The NICE-PAP study will examine how&#xD;
      the physiologic traits that cause OSA in each individual impact CPAP effectiveness and can&#xD;
      lead to personalized OSA treatments that improve patient lives.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Most patients with OSA who are prescribed the gold-standard therapy, CPAP, are ineffectively&#xD;
      treated. This is due to 1) poor CPAP adherence, 2) high residual apnea in 20% of users (low&#xD;
      efficacy) and 3) inconsistent symptom improvement. To improve CPAP effectiveness, we propose&#xD;
      to address novel physiologic targets that cause OSA in each individual: arousability (arousal&#xD;
      threshold), ventilatory control sensitivity (loop gain) and pharyngeal muscle compensation.&#xD;
&#xD;
      Our overall objective is to determine the contribution of these traits to CPAP effectiveness&#xD;
      independently of established biological, psychological and social predictors. This study&#xD;
      leverages state-of-the art sleep study analysis tools and validated measures of the&#xD;
      determinants of CPAP effectiveness to create a pragmatic, prospective cohort (n=267) of OSA&#xD;
      patients. This unique dataset will help determine whether physiologic causes of OSA influence&#xD;
      CPAP adherence, efficacy, sleep quality, symptoms, function and quality of life. The results&#xD;
      will inform design and conduct of a randomized clinical trial designed to modify physiologic&#xD;
      traits such as easy arousability to improve CPAP effectiveness and other patient-centered&#xD;
      outcomes in OSA patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">August 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>CPAP adherence</measure>
    <time_frame>6 months</time_frame>
    <description>average daily CPAP use (hours/night)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CPAP efficacy</measure>
    <time_frame>6 months</time_frame>
    <description>average daily residual apnea hypopnea index on CPAP (events/hour)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OSA related quality of life measured by Functional Outcomes of Sleep Questionnaire (FOSQ) short form</measure>
    <time_frame>6 months</time_frame>
    <description>FOSQ short form average scores, Range 0 - 5, higher scores reflect worse quality of life and function.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CPAP adherence (dichotomous)</measure>
    <time_frame>3 months</time_frame>
    <description>dichotomized measure of &gt;4 hours/night for &gt;70% of nights</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CPAP adherence</measure>
    <time_frame>1 month</time_frame>
    <description>average daily CPAP use (hours/night)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CPAP adherence</measure>
    <time_frame>12 months</time_frame>
    <description>average daily CPAP use (hours/night)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CPAP efficacy (dichotomous)</measure>
    <time_frame>6 months</time_frame>
    <description>residual AHI &gt;=10/hour</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep quality: Patient-Reported Outcomes Measurement Information System (PROMIS) scores</measure>
    <time_frame>6 months</time_frame>
    <description>PROMIS scores, Range 0 - 40, higher scores reflect worse quality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep related impairment: Patient-Reported Outcomes Measurement Information System (PROMIS) scores</measure>
    <time_frame>6 months</time_frame>
    <description>PROMIS - impairment scores, range 0 - 40, higher scores reflect greater impairment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insomnia: Insomnia Severity Index (ISI)</measure>
    <time_frame>6 months</time_frame>
    <description>ISI scores, Range 0 - 28; higher scores reflect higher insomnia burden/severity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epworth sleepiness scale</measure>
    <time_frame>6 months</time_frame>
    <description>Epworth sleepiness scale scores, Range 0 - 24; higher scores signify greater sleepiness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety: Hospital Anxiety and Depression Scale - Anxiety subscale scores</measure>
    <time_frame>6 months</time_frame>
    <description>Hospital Anxiety and Depression Scale - Anxiety subscale scores range 0 - 21; higher scores signify greater anxiety symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression: Hospital Anxiety and Depression Scale - Depression subscale scores</measure>
    <time_frame>6 months</time_frame>
    <description>Hospital Anxiety and Depression Scale - Depression subscale scores, Range 0 - 21; higher scores signify greater depression symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Attention</measure>
    <time_frame>6 months</time_frame>
    <description>median reaction time and mean slowest 10% reaction time from a 5-min smartphone-based psychomotor vigilance test.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">267</enrollment>
  <condition>Obstructive Sleep Apnea</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CPAP (all patients receive CPAP as part of routine clinical care)</intervention_name>
    <description>Continuous positive airway pressure</description>
    <other_name>Exposure: arousal threshold</other_name>
    <other_name>Exposure: loop gain</other_name>
    <other_name>Exposure: pharyngeal collapsibility</other_name>
    <other_name>Exposure: pharyngeal muscle compensation</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The participants will be drawn from the clinical population of patients referred for&#xD;
        evaluation to the Yale New Haven Hospital Sleep Center. Currently, 38% of patients at YNHH&#xD;
        with diagnosis of OSA are women, 65% are White, 12% Black, 10% Hispanic, 1% Asian, 1%&#xD;
        Pacific Islander and remainder selecting other or unknown classification. We expect a&#xD;
        similar proportion of enrolled subjects. Inclusion of vulnerable population subjects such&#xD;
        prisoners or institutionalized individuals will be rare as these patients are infrequently&#xD;
        evaluated sleep medicine clinics, however, they will not be excluded. Subjects who are&#xD;
        undocumented immigrants to the U.S. will not be excluded and will undergo an informed&#xD;
        consent process individualized in each encounter. Inclusion/exclusion criteria are noted&#xD;
        above.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age of &gt;18 years&#xD;
&#xD;
          2. Newly diagnosed OSA naïve to CPAP&#xD;
&#xD;
          3. Apnea hypopnea index (AHI) ≥5/hr on in-laboratory polysomnography or home sleep test&#xD;
             acquired and scored using standard criteria(59)&#xD;
&#xD;
          4. Referred for CPAP adherence management at Yale New Haven Hospital Sleep Center&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Need for supplemental oxygen&#xD;
&#xD;
          2. Central apnea index comprising &gt;50% of the AHI&#xD;
&#xD;
          3. Treatment recommendation with another modality (e.g., Bilevel PAP, Adaptive&#xD;
             Servo-Ventilation, Automatic Volume Pressure Assured Pressure Support)&#xD;
&#xD;
          4. A referral for a sleep disorder other than OSA (i.e., narcolepsy, sleep related&#xD;
             movement disorder, circadian rhythm sleep-wake disorder)&#xD;
&#xD;
          5. Prior CPAP or Auto-CPAP use over the past 3 years&#xD;
&#xD;
          6. Unstable medical or mental health condition (e.g., decompensated heart failure,&#xD;
             end-stage chronic obstructive pulmonary disease, end stage renal disease, psychosis)&#xD;
&#xD;
          7. Inability to participate in the informed consent process (e.g., cognitive impairment)&#xD;
&#xD;
          8. Pregnancy&#xD;
&#xD;
          9. Non-English language use as only means of communication (because the research budget&#xD;
             does not provide adequate resources to ensure that the needs of non-English speaking&#xD;
             patients can be adequately addressed)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Andrey Zinchuk, MD, MHS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrey Zinchuk, MD, MHS</last_name>
    <phone>475-655-6199</phone>
    <email>andrey.zinchuk@yale.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Iouri Kreinin, MD</last_name>
    <email>iouri.kreinin@yale.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Yale New Haven Hospital Sleep Center</name>
      <address>
        <city>North Haven</city>
        <state>Connecticut</state>
        <zip>06473</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>andrey zinchuk, MD, MHS</last_name>
      <phone>203-733-9528</phone>
      <email>andrey.zinchuk@yale.edu</email>
    </contact>
    <contact_backup>
      <last_name>Iouri Kreinin</last_name>
      <email>iouri.kreinin@yale.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Andrey Zinchuk, MD, MHS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Zinchuk A, Edwards BA, Jeon S, Koo BB, Concato J, Sands S, Wellman A, Yaggi HK. Prevalence, Associated Clinical Features, and Impact on Continuous Positive Airway Pressure Use of a Low Respiratory Arousal Threshold Among Male United States Veterans With Obstructive Sleep Apnea. J Clin Sleep Med. 2018 May 15;14(5):809-817. doi: 10.5664/jcsm.7112.</citation>
    <PMID>29734986</PMID>
  </reference>
  <reference>
    <citation>Zinchuk AV, Redeker NS, Chu JH, Liang J, Stepnowsky C, Brandt CA, Bravata DM, Wellman A, Sands SA, Yaggi HK. Physiological Traits and Adherence to Obstructive Sleep Apnea Treatment in Patients with Stroke. Am J Respir Crit Care Med. 2020 Jun 15;201(12):1568-1572. doi: 10.1164/rccm.201911-2203LE.</citation>
    <PMID>32083949</PMID>
  </reference>
  <reference>
    <citation>Zinchuk AV, Chu JH, Liang J, Celik Y, Op de Beeck S, Redeker NS, Wellman A, Yaggi HK, Peker Y, Sands SA. Physiological Traits and Adherence to Sleep Apnea Therapy in Individuals with Coronary Artery Disease. Am J Respir Crit Care Med. 2021 Sep 15;204(6):703-712. doi: 10.1164/rccm.202101-0055OC.</citation>
    <PMID>34156917</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 22, 2021</study_first_submitted>
  <study_first_submitted_qc>September 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2021</study_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yale University</investigator_affiliation>
    <investigator_full_name>Andrey Zinchuk</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Continuous positive airway pressure (CPAP)</keyword>
  <keyword>Physiologic sleep apnea traits (endotypes)</keyword>
  <keyword>CPAP adherence</keyword>
  <keyword>CPAP efficacy</keyword>
  <keyword>Patient-centered sleep apnea outcomes</keyword>
  <keyword>Precision medicine</keyword>
  <keyword>Arousal threshold</keyword>
  <keyword>Loop gain</keyword>
  <keyword>Pharyngeal collapsibility</keyword>
  <keyword>Pharyngeal muscle compensation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

